STAGING OF KELOID DISORDER:

In his most recent publication, Neck Keloids: evaluation of risk factors and recommendation for keloid staging system" Dr. Tirgan has designed a staging system that allows for proper categorization and grouping of keloid patients into various stages. It is common sense that a patient with only one small keloid lesion will have a different outcome than one who has numerous large keloid lesions.

Staging systems have been used in management of cancer patients. It is common sense that a patient with very small, stage one breast cancer will have a different outcome from patients with metastatic, stage four breast cancer. Dr. Tirgan, in devising his #Keloid Staging System has followed the same methodology that is utilized in staging cancers. TNM cancer staging system has been used for several decades and allows proper stage grouping of cancer patients. A great majority of caner treatments, clinical trials, and standard treatments are guided by the TNM staging of the cancer at any given time. Conduct and interpretation of the result of oncology clinical trials are virtually dependent on this staging system.

Without such a staging system for Keloid Disorder, the interpretation of all published keloid study results is very difficult. For example, when a study looks at the rate of recurrence of ear keloids after surgery, common sense tells us that patients who only have one keloid on one ear, will have a different rate of recurrence from those who have numerous keloids on their skin. Also, those who have had prior surgical removal of their keloids will have a much higher rate of recurrence than those patients who have never had surgery before.

To assess each keloid patient properly, to better understand the natural history of this disorder, and to be able to compare future keloid study results among various patients groups, we clearly need a staging system that can allow us to describe the severity keloid disorder based on the size, location and/or extent of the keloidal lesions; as well as history of surgery or radiation therapy, and perhaps other factors that are currently unknown to us. It is quite conceivable that proper management of keloid patients could be guided by such a staging system. Dr. Tirgan's staging system for keloid disorder is a method that can stratify for such preexisting inherent risks of recurrence, such as response to prior treatments, positive family history, age, gender, race, and so forth.

A well-designed clinical staging system will need to be validated by review of retrospective studies as well as planned prospective clinical trials. Dr. Tirgan is leading the efforts to refine this staging system. KRF invites collaborations to implement and refine this proposed staging system.

CLINICAL STAGING AND CLASSIFICATION OF KELOID LESIONS:

Stage 0: Genetically predisposed. At least one parent has had keloids. Index person has no clinical evidence or history of keloid or any hypertrophic scars. Stage I: Presence of only one keloidal lesion.

Stage 1A: Presence of only one keloidal lesion that measures no greater than 2 centimeters in any dimension.

Stage 1B: Presence of only one keloidal lesion that measures 2.1 - 10 centimeters in any dimension.

Stage 1C: Presence of only one keloidal lesion that measures greater than 10 centimeters in any dimension.

Stage II: Presence of multiple keloidal lesion. The sum of the largest diameter of the keloids is up to 30 centimeters.

Stage II A: Keloids measure ≤ 2 centimeters in largest diameter; the sum of the largest diameter of all keloids measures 10 centimeters or less.

Stage II B: Keloids measure ≤ 10 centimeters in largest diameter, at least one keloid measures 2.1 - 10 centimeters in its largest diameter; the sum of the largest diameter of all keloids measures 10.1 - 20 centimeters.

Stage II C: At least one keloid measures 10 centimeters in largest diameter; the sum of the largest diameter of all keloids measures up to 30 centimeters.

Stage III: Presence of multiple keloidal lesions; the sum of the largest diameter of the keloids measures 30.1 - 50 centimeters.

Stage III A: Keloids measure ≤ 2 centimeters in largest diameter; the sum of the largest diameter of all keloids measure 30.1 - 40 centimeters.

Stage III B: Keloids measure ≤ 10 centimeters in largest diameter; at least one keloid measures 2.1 - 10 centimeters in its largest diameter; the sum of the largest diameter of all keloids measures 30.1 - 40 centimeters.

Stage III C: At least one keloid measures 10 centimeters in largest diameter; the sum of the largest diameter of all keloids measures 30.1 - 50 centimeters.

Stage IV: Presence of multiple keloidal lesions; the sum of the largest diameter of the keloids is greater than 50 centimeters.

Stage IV A: Keloids measure ≤ 2 centimeters in largest diameter; the sum of the largest diameter of all keloids measures greater than 50 centimeters.

Stage IV B: Keloids measure ≤ 10 centimeters in largest diameter; at least one keloid measures 2.1 - 10 centimeters in its largest diameter. The sum of the largest diameter of all keloids measures greater than 50 centimeters.

Stage IV C: At least one keloid measures greater than 10 centimeters in its largest diameter; the sum of the largest diameter of all keloids to measure greater than 50 centimeters.
LATEST NEWS

    Notice of 501 (C)(3) Status:

    (February 1, 2017) Keloid Research Foundation has been determined by the US Internal Revenue Service (IRS) to be exempt from federal income tax under Internal Revenue Code (IRC) Section 501(C)(3). Donors can deduct contributions they make to KRF under IRC Section 170. Click here to view the 501(C)(3) Exemption Document.

    Journal of Keloid Research:

    (December 3, 2016)KRF is proud to announce establishment of Keloid Research, an open access scientific publication of the Keloid Research Foundation. Until now, keloid manuscripts have been published in a variety of journals. Our goal is to create a centralized publishing platform for all researchers who are passionate about this disorder, so that relevant clinical and laboratory research can be published in one place and under one umbrella. The journal is aiming to provide an international forum for the publication of original work, describing basic science, translational and clinical investigations in keloid disorder.

    Keloid Staging System:

    (August 19, 2016) In his most recent publication, "Neck Keloids: evaluation of risk factors and recommendation for keloid staging system" Dr. Tirgan has designed a staging system that allows for proper categorization and grouping of keloid patients into various stages.

    To assess each keloid patient properly, to better understand the natural history of this disorder, and to be able to compare future keloid study results among various patients groups, we clearly need a staging system that can allow us to describe the severity keloid disorder based on the size, location and/or extent of the keloidal lesions; as well as history of surgery or radiation therapy, and perhaps other factors that are currently unknown to us. Please click HERE to read more.

    International Keloid Symposium:

    (March 11, 2016) KRF is proudly announcing that the 1st ever will be held on September 8 - 9, 2016 at Rockefeller University in New York. KRF Extends its gratitude to Rockefeller University for hosting this meeting and its support for keloid research. Click on the image below to be directed to the symposium website.

  • March 11, 2016
  • Dr. Patricia Danielsen has joined the board of Directors of KRF:

    KRF is pleased to announce that Dr. Patricia Danielsen has joined the board of directors of KRF. Dr. Danielsen is a dermatologist at the Department of Dermatology and Copenhagen Wound Healing Center, Copenhagen University Hospital, Denmark. She has a PhD in wound healing and scar treatment science and a continuing academic career with a special focus on keloid scar disease. We welcome Dr. Danielsen and look forward to working with her in strengthening KRF.

  • November 1, 2015
  • KRF presentations at ETRS 2015 meeting:
  • Dr. Michael H. Tirgan was invited and gave two talks on Keloid Disorder at the Keloid Satellite Symposium during the 7th Joint Meeting of the European Tissue Repair Society & the Wound Healing Society that was held 21-23 October 2015 in Copenhagen, Denmark.

  • August 15, 2015
  • Atlas of Ear Keloids:
  • KRF is pleased to announce publication of it first sponsored book, Atlas of Ear Keloids. This full color atlas, authored by Dr. Michael Tirgan, provides an insight into natural history of ear keloids. With over 130 full color images of ear keloids, Dr. Tirgan provides a solid proof that surgery is not a treatment for keloid disorder.

    Atlas of Ear Keloids by Dr. Michael H. Tirgan

  • August 1, 2015
  • KRF presenting at ETRS 2015 meeting:
  • KRF was able to arrange for a scientific session dedicated to keloid research the 7th Joint Meeting of the European Tissue Repair Society & the Wound Healing Society that will be held 21-23 October 2015 in Copenhagen, Denmark. This will be the very first dedicated scientific session that KRF has been able to organize.

  • November 11, 2011
  • KRF Formally Registered in New York State
  • KRF is pleased to announce that its Certificate of Incorporation was accepted and filled by the State of New York. KRF is now able to conduct fund raising activities to support conduct of much needed research in the field of Keloid.
  • October 18, 2011
  • Grant Approval from Rockefeller University
  • KRF is pleased to announce that Dr. Tirgan's proposal to study "Pathogenesis of Keloid" was approved by the Rockefeller University Center for Clinical and Translational Sciences. (RUCCTS Grant # 2UL1RR024143 from the National Center for Research Resources, National Institutes of Health). We thank Rockefeller University for extending support to our fight against keloid disorder. www.KeloidTissueBank.com is the official website of the main study.
  • October 14, 2011
  • Dr. James N. Musyoka, joins KRF
  • KRF is pleased to announce that Dr. Musyoka has joined KRF. Dr. Musyoka has just completed his PhD with focus on would healing and keloid research and has previously conducted laboratory research in this area. We welcome Dr. Musyoka as a new member of KRF.
  • August 4, 2011
  • Dr. Djoned Sananto joins KRF
  • KRF is pleased to announce that Dr. Sananto, Head of Plastic Surgery Department at Haji General Hospital in Indonesia, has joined KRF. Dr. Sananto has strong interest in keloid disorder, actively treats patients with keloids, has previously conducted laboratory research in keloid and published the study results. We welcome Dr. Sananto as a new member of KRF.
  • July 28, 2011
  • Advanced Pathology Laboratory Partners with KRF
  • KRF is pleased to announce that the Director of Advanced Pathology Laboratory, Dr. Ali Daneshvar, has made a long term commitment to serve as the Tissue Bank arm of KRF. Advanced Pathology Laboratory is a CLIA certified full service pathology laboratory, located in Northfiled, New Jersey.
  • July 21, 2011
  • KRF Appoints General Counsel
  • KRF is pleased to announce appointment of its General Counsel. Attorney Ronald R. Benjamin of Binghamton, New York has been appointed General Counsel for Keloid Research Foundation. He will oversee all legal matters that concern operations of KRF. Mr. Benjamin has been practicing public interest law since 1979.
  • July 18, 2011
  • Certificate of Incorporation for KRF
  • The Certificate of Incorporation for KRF was completed by three initial board members, Michael Tirgan, MD acting as the Medical Officer, Nadereh Nouhi acting as the Business Manager and Alexander Duggan acting as the Patient Advocate and Liaison.